Skip to content

A randomized controlled clinical trial of Zhihuixin versus cognitive behavioral therapy for sleep-related problems in children with neurodevelopmental disorders

A randomized controlled clinical trial of Zhihuixin versus cognitive behavioral therapy for sleep-related problems in children with neurodevelopmental disorders

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500112559
Enrollment
Unknown
Registered
2025-11-17
Start date
2025-12-01
Completion date
Unknown
Last updated
2025-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neurodevelopmental Disorders

Interventions

Experimental Group:Zhihuisu Supplementation Protocol:Duration: 12 weeks Age 1-3 years: One sachet of *Zhihuisu-1* administered orally each morning Age 4-10 years: Two sachets of *Zhihuisu-2* administe
Control Group:Cognitive Behavioral Therapy (CBT) Intervention :Duration: 12 weeks Frequency: Once-weekly 45-minute sessions"

Sponsors

Guangzhou Women and Children's Medical Center
Lead Sponsor

Eligibility

Sex/Gender
All
Age
1 Years to 10 Years

Inclusion criteria

Inclusion criteria: (1) Aged 1-10 years old, meeting the diagnostic and Statistical Manual of Mental Disorders, fifth edition (DSM-5) diagnostic criteria for neurodevelopmental disorders; (2) Sleep-related problems (CSHQ >=42, sleep onset latency: >30 minutes or number of nocturnal awakenings >=3 times/night); (3) Legal guardians or legal representatives signed written informed consents and promised to complete the 3-month follow-up and the whole course of the intervention. Written informed consent was obtained from children 8 years of age or older.

Exclusion criteria

Exclusion criteria: (1) Complicated with severe organic diseases (such as congenital heart disease, hepatic and renal insufficiency); (2) Use of psychotropic drugs (such as atomoxetine, melatonin, treserin, etc.) that may affect sleep or mood function within the past 3 months, or participating in other similar clinical trials; (3) Known to be allergic to the core components of Zhibitrin (ferulic acid, PS, Angelica dahurica extract) or have a history of severe food allergy; (4) Children were unable to cooperate with intervention and evaluation due to behavioral problems (such as aggressive behavior and severe self-injury).

Design outcomes

Primary

MeasureTime frame
Children’s Sleep Habits Questionnaire;Brief Infant Sleep Questionnaire;

Secondary

MeasureTime frame
Infant Behavior Questionnaire;(Conners' Parent Rating Scale - Revised,CPRS-R);PedsQL;

Countries

China

Contacts

Public ContactKaishou Xu

Guangzhou Women and Children's Medical Center, Affiliated with Guangzhou Medical University

xksyi@126.com+86 134 2225 0582

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026